Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery DiseaseJunnichi Ishii, Ryozo Nagai, Kosuke Kashiwabara et al.|Journal of Atherosclerosis and Thrombosis|2021Cited by 27
A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)Katsutoshi Oda, Hiroyuki Aburatani, Akira Nishijima et al.|Gynecologic Oncology|2023Cited by 0
777P A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)Katsutoshi Oda, K. Hasegawa, Daisuke Shintani et al.|Annals of Oncology|2024Cited by 0
987c: PLASTIC STENTS VS. LUMEN-APPOSING METAL STENT FOR ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF PANCREATIC PSUEDOCYSTS: A MULTICENTER, RANDOMISED CONTROLLED, NONINFERIORITY TRIAL (WONDER-02)Yousuke Nakai, Takeshi Ogura, Nao Fujimori et al.|Gastroenterology|2025Cited by 0
Mutational Signature‐Based Biomarker for Phase <scp>II</scp> Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian CancerKatsutoshi Oda, Kosei Hasegawa, Kosuke Yoshihara et al.|Cancer Science|2026Cited by 0